Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2001-07-26
2010-02-23
Canella, Karen A (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230, C435S063000, C435S064000
Reexamination Certificate
active
07666609
ABSTRACT:
This invention relates to monoclonal antibodies that recognize an antigen specific to melanocytic lesions. These antibodies are useful in methods of isolating melanoma cells and diagnosing melanocytic lesions. These antibodies are also useful for immunotherapy against melanoma.
REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4311688 (1982-01-01), Burchiel et al.
patent: 4472371 (1984-09-01), Burchiel et al.
patent: 4478815 (1984-10-01), Burchiel et al.
patent: 4478818 (1984-10-01), Shell et al.
patent: RE32417 (1987-05-01), Burchiel et al.
patent: 4732864 (1988-03-01), Tolman
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5317091 (1994-05-01), Subramanian
patent: 5475096 (1995-12-01), Gold et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5595877 (1997-01-01), Gold et al.
patent: 5660985 (1997-08-01), Pieken et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: WO 97/47271 (1997-12-01), None
patent: WO 98/04282 (1998-02-01), None
patent: WO 98/16238 (1998-04-01), None
patent: WO 98/24884 (1998-06-01), None
The abstract of Chen et al (Journal of Molecular Medicine, May 1998, Vol. 76, p. B11).
Wilson et al, Biochem Biophys Research Commun, 1981, Vol. 101, pp. 1047-1051 (abstract).
McCarthy et al, Biochemistry, 1988, Vol. 27, pp. 1380-1388), (abstract).
The abstract of Sekiguchi et al (Seikagaku, 1989, 61, pp. 89-93).
Natali et al (British Journal of Cancer, 1995, vol. 71, pp. 1243-1247).
Trefzer et al, BMC Cancer, 2006, vol. 6, pp. 1-12.
Kerr and Thorpe (Immunochemistry LabFax, pp. xi, X and 120).
Aamdal et al. “Immunomagnetie Detection of Melanoma Cells in Bone Marrow and Blood”.
Adema et al. “Molecular Characterization of the Melanocyte Lineage-Specific Antigen gp100” J Biol. Chem: 269:20126-20133 (1994).
Argenyi et al. “S100 Protein-Negative Malignant Melanoma: Fact or Fiction? A Light-Microscopic and Immuno-Histochemical Study” Am. J. Demiatopathol. 16:233-240 (1994).
Brooks et al. J. “Subtractive Immunization Yields Monoclonal Antibodies that Specifically Inhibit Metastasis” Cell Biol. 122(6):1351-1359 (1993).
Cochran et al. “Detection of S100 Protein as an Aid to the Identification of Melanocytic Tumors” Int. J. Cancer 30:295-297 (1982).
Cohen et al. “Production and Characterisation of an Antimelanoma Mcinoclonal Antibody KBA.62 Using a New Melanoma Cell Line Reactive on Paraffin Wax Embedded Sections” J. Clin. Pathol. 48:826-831 (1995).
Colombari et al. “Distribution of Melanoma Specific Antibody (HMB-45) in Benign and Malignant Melanocytic Tumors” Virchows Archiv. A Pathol Anat. 413:17-24 (1988).
Drier et al. “S100. Protein Immunoreactivity in Poorly Differentiated Carcinomas. Immuno-Histochemical Comparison with Malignant Melanoma” Arch. Pathol. Lab. Med. 111:447-452 (1987).
Emery and Harris. “Strategies for Humanizing Antibodies” Chapter 6In Antibody Engineering2ndEd. pp. 159-183 (1995).
Esclamado et al. “Unique Proteins Defined by MonoclonalAntibodies Specific for Human Melanoma. Some Potential Clinical Applications” Am. J. Surg. 152:376-385 (1986).
Frye et al. “Detection of Amplified Oncogenes by Differential Polymerase Chain Reaction” Oncogene 4:1153-1157 (1987).
Gatter et al. “An Immunocytochemical Study. Of Malignant Melanoma and its Differential Diagnosis from Other Malignant Tumors” J. Clin. Pathol. 38:1353-1357 (1985).
Giomo. “A Comparison of Two Immunoperoxidase Staining Methods Based on the Avidin-Biotin Interaction” Diag. Immununol. 2:161-166 (1984).
Gown et al. “Monoclonal Antibodies Spevific for Melanocytic Tumors Distinguished Subpopulations of Melanocytes” Am. J. Pathol. 123:195-203. (1986).
Guo et al. “Inhibition of Human Melanoma Growth and Metstasis In Vivo by Anti-CD44 Monoclonal Antibody” Cancer Res. 54:1561-1565 (1994).
Hachisuka et al. “Immuno-Histochemical Study of S100. Protein and Neuron Specific Enolase )NSE) in Melanocytes and the Related Tumors” Acta Histochem. 80:215-223 (1986).
Harlow and Lane. “Immunoaffinity Purification” Chapter 13In Antibodies- A Laboratory Manualcold Spring Harbor Laboratory pp. 511-552 (1988).
Harlow and Lane. Chapter 12 & 14In Antibodies- A Laboratory ManualCold .Spring Harbor Laboratory pp. 471-510 & 553-612 (1988).
Herrera and Hancock. “Specificity of Antibody HMB-45” Arch. Pathol. La. Med. 116:900-901 (1992).
Irie et al. “Regression of Cutaneous Metastatic Melanoma by Intralesional Injection with Human Monoclonal Antibody to Ganglioside GD2” Proc..Natl. Acad. Sci. USA 83:8694-8698 (1986).
Kindblom et al. “S100 Protein in Melanocytic Tumors. An Inununo-Histochemical Investigation of Benign and Malignant Melanocytic Tumors and Metastases of Malignant Melanoma and a Characterization of the Antigen in Comparison to Human Brain” Acta. Pathol. Microbiol. Imrnunol. Scand. 92:219-230 (1984).
Köhler et al. “Derivation of Specific Antibody. Producing Tissue Culture and Tumor Lines by Cell Fusion” Eur. J. Immunol. 6:511-519 (1976).
Mackie et al. “Use of NK1 C3 Monoclonal Antibody in the Assessment of Benign and Malignant Melanocytic Lesions” J. Clin. Pathol. 37:367-372 (1984) .
Mottolese et al. “Immunocytochemical Diagnosis of Amelanotic Metastatic Melanoma Using Monoclonal Antibodies HMB-45 and Ep1-3” Melanoma Res. 4:53-58 (1994).
Nakajima et al. “Immuno-Histochemical Demonstration of S100 Protein in Malignant Melanoma and Pigmented Nevus and its Diagnostic Application” Cancer 50:912-918 (1982).
Ordonez et al. “Comparison of HMB-45 Monoclonal Antibody and S100 Protein in the Immuno-Histochemical Diagnosis of Melanoma” Am. J. Clin. Pathol. 90:385-390 (1988).
Palazzo and Duray. “Typical, Dysplastic, Congenital, and Spitz Nevi: A Comparative Immuno-Histochemical Study” Hum. Pathol. 20:341-346 (1989).
Rothman et al. “Structure and Expression of Germ Line Immunoglobulin Heavy-Chain ε Transcripts: Interleukin-4 Plus Lipopolysaccharide-Directed Switching to Cε” Molecular and Cellular Biology 10(4):1672-1679 (1990).
Serafini et al. “Technetium —99m Labeled Monoclonal Antibodies in the Detection of Metastatic Melanoma” Clinical Nuclear Medicine 14(8):580-587 (1989).
Shi et al. “Antigen Retrieval in Formalin-Fixed, Paraffin-Embedded Tissues: An Enhancement Method for Immuno-Histochemical Staining Based on Microwave Oven Heating of Tissue Sections” J. Histochem Cytochem. 39:741-748 (1991).
Smoller et al. “HMB-45 Staining of Dysplastic Nevi. Support for a Spectrum of Progression Toward Melanoma” A. J. Surg. Pathol. 13:680-684 (1989).
Smoller. “Immunohistochemistry in the Diagnosis of Melanocytic Neoplasms” Pathology: State of the Art Reviews 2:371-383 (1994).
Springall et al. “The Value of S100 Immunostaining as a Diagnostic Tool in Human Malignant Melanomas. A Comparative Study Using S100 and Neuron-Specific Enolase Antibodies” Virchows Arch. Pathol. Anat. Histopathol. 400:331-343 (1983).
Stefansson et al. “Distribution of S100 Protein Outside the Central Nervous System” Brain Res. 234:309-317 (1982).
Stefansson et al. “S100 Protein in Human Chondrocytes” Nature 295:63-64 (1982).
Sun et al. “Antibody HMB-45 Identifies the Cells of Blue Nevi. An Immuno-Histochemical Study on Paraffin Sections” Am. J. Surg. Pathol. 14:748-751 (1990).
Swerdlow et al. “Risks of Second Primary Malignancy in Patients with Cutaneous and Ocular Melanoma in Denmark, 1943-1989” Int. J. Cancer 61:773-779 (1995).
Tabuchi et al. “A S100 Protein in Human Glial Tumors. Qualitative and Quantitative Studies” Aca Neurochir. Wien 65:239-251(1982).
Trefzer et al. “SM5-1: A New Monoclonal Antibody Which is Highly Sensitive and Specific for Melanocytic Tumors” Journal of Dermatological Scien
Guo Yajun
Ma Jing
Canella Karen A
Fish & Richardson P.C.
Shanghai CP GuoJian Pharmaceutical Co. Ltd.
LandOfFree
Method and composition for diagnosis of melanocytic lesions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for diagnosis of melanocytic lesions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for diagnosis of melanocytic lesions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223693